Document is current
Any future updates will be listed below
-
Authors
Call, Justin A
Anderson, Ian
Winer, Ira
Orr, Douglas
Yeku, Oladapo
Richardson, Debra L
Zhang, Jian
Lee, Elizabeth
Konecny, Gottfried
Li, Ning
Patel, Sandip P
Wu, Lin
Wang, Jing
Zhang, Jun
Cheng, Ying
Wu, Xiaohua
Hunder, Naomi
Lu, Lian
Ma, Sharon
Song, Eric
Hamilton, Erika
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05579366 at ClinicalTrials.govnct05579366 at ClinicalTrials.govDocuments that mention this clinical trial
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0708
Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps3157
The clinical landscape of antibody-drug conjugates in endometrial cancer
https://doi.org/10.1136/ijgc-2024-005607
Documents that mention this clinical trial
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0708
Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps3157
The clinical landscape of antibody-drug conjugates in endometrial cancer
https://doi.org/10.1136/ijgc-2024-005607
- License Information
